Apixaban concentration variability and relation to clinical outcomes in real-life patients with atrial fibrillation
Abstract In some clinical situations, measurements of anticoagulant effect of apixaban may be needed. We investigated the inter- and intra-individual apixaban variability in patients with atrial fibrillation and correlated these results with clinical outcome. We included 62 patients receiving either...
Guardado en:
Autores principales: | Alenka Mavri, Nina Vene, Mojca Božič-Mijovski, Marko Miklič, Lisbeth Söderblom, Anton Pohanka, Rickard E. Malmström, Jovan Antovic |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0924ed74aa5d49abbeb7d5aa319ba73a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The in vitro addition of idarucizumab to plasma samples from patients increases thrombin generation
por: Mojca Božič Mijovski, et al.
Publicado: (2021) -
Economic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the Netherlands.
por: Jelena Stevanović, et al.
Publicado: (2014) -
Cost-effectiveness analysis of apixaban versus vitamin K antagonists for antithrombotic therapy in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention in Spain.
por: Simone Rivolo, et al.
Publicado: (2021) -
Cost-effectiveness analysis of apixaban versus vitamin K antagonists for antithrombotic therapy in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention in Spain
por: Simone Rivolo, et al.
Publicado: (2021) -
Atrial Myopathy Underlying Atrial Fibrillation
por: Harold Rivner, et al.
Publicado: (2020)